We are approaching World Cancer Day 2023. Cancer has a global impact of around 20 million new cases each year, remaining a major public health challenge. In the fight against this disease, we at TIEFENBACHER GROUP are committed to deliver better affordable medicines for cancer patients around the world.
Hereby we are always aiming to improve patients’ lives by developing added value medicines with a better posology, additional strengths, suitable fixed dosage combinations, or personalized therapies by combining medicines with smart e-health solutions – just to name a few of our differentiated and innovative product solutions.
TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent cancer drugs in its launch pipeline which are planned to be developed and manufactured in our new state-of-the-art high potent facilities in Hyderabad, India.
AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on: www.aet.eu
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
